Amir Inamdar
Chief Medical Officer Helus Pharma
Amir is a trained psychiatrist and a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, UK. Amir has over 25 years of drug development experience. He has worked at a number of companies including GlaxoSmithKline, Takeda and AstraZeneca, where he has progressed drugs from preclinical development candidates through to first in human and early phase clinical trials. He has led the design of and successfully delivered proof-of-concept studies in addition to leading teams through the design and execution of phase 3 pivotal studies, filing of INDs/ CTAs and NDAs/ MAAs (marketing authorization applications).
He has worked across multiple indications in psychiatry, including schizophrenia, depression, bipolar disorder, treatment resistant mental illnesses and substance use disorders where he has led multidisciplinary teams, providing strategic direction and clinical and scientific guidance.
In his current role as Chief Medical Officer at Cybin, Amir leads a team responsible for program leadership and oversees clinical development strategies and progressing novel compounds from preclinical development to proof of concept and ultimately to approval.
Amir has published across a wide range of clinical topics and brings translational and clinical scientific insight to our programmes. He is also a key member and recognized leader in the industry, speaking regularly at scientific conferences and discussion panels, participating in and leading cross-industry initiatives in scientific societies.
Seminars
Interventional psychiatry is advancing rapidly, but commercializing new treatments in this space requires navigating scientific complexity, clinical workflow integration, regulatory ambiguity and evolving payer expectations. This workshop brings together leaders across drug development, clinical services, digital therapeutics and health system innovation to unpack what it takes to bring interventional psychiatric treatments to market effectively and responsibly. Through real world case studies and cross sector perspectives, attendees will explore how to position novel modalities, build scalable delivery models, integrate biomarkers and patient selection tools, evaluate reimbursement pathways, and ensure safe, consistent implementation across diverse clinical environments.
- Define the commercial, clinical and operational considerations required to bring interventional psychiatric treatments to market, including positioning, differentiation and workflow integration
- Examine the infrastructure, training, safety and scalability requirements needed for real world delivery across clinics, health systems and community based care settings
- Identify viable reimbursement and market access pathways by understanding payer priorities, value demonstration, and the evidence needed to support sustainable adoption
